/BDRX
BDRX Stock - Biodexa Pharmaceuticals Plc
Healthcare|BiotechnologyNASDAQ
$3.64-12.29%
$0.51 (-12.29%) • Dec 19
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BDRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.60 – $3.68
TARGET (TP)$4.19
STOP LOSS$3.35
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.96
52W High$92.00
52W Low$3.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $381,000 | $699,000 | $578,000 | $343,000 |
| Gross Profit | $-5,437,000 | $-3,686,000 | $-4,412,000 | $-4,076,000 | $-5,725,000 |
| Gross Margin | N/A | -967.5% | -631.2% | -705.2% | -1669.1% |
| Operating Income | $-9,199,000 | $-8,014,000 | $-8,932,000 | $-6,998,000 | $-23,040,000 |
| Net Income | $-5,729,000 | $-7,079,000 | $-7,656,000 | $-5,460,000 | $-22,189,000 |
| Net Margin | N/A | -1858.0% | -1095.3% | -944.6% | -6469.1% |
| EPS | $-115700.00 | $-22900.00 | $-494300.00 | $-352500.00 | $-1432700.00 |
Company Overview
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$8
Average Target
↑ 119.8% Upside
Now
$8
Low
$8
Average
$8
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 8th 2024 | Ladenburg Thalmann | Initiation | Buy | $8 |
Earnings History & Surprises
BDRXBeat Rate
67%
Last 3 quarters
Avg Surprise
-1723481041.5%
EPS vs Estimate
Beats / Misses
2/1
Last 12 quarters
Latest EPS
$-205266.60
Q3 2025
EPS Surprise History
Q2 19
No data
Q4 19
No data
Q4 20
No data
Q2 21
No data
Q3 23
No data
Q3 24
+92.4%
$-0.02vs$-0.22
Q2 25
+92.2%
$-0.00vs$-0.01
Q3 25
-5170443309.1%
$-205266.60vs$-0.00
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 12, 2025 | $-0.00 | $-205266.60 | -5170443309.1% | ✗ MISS |
Q2 2025 | Apr 11, 2025 | $-0.01 | $-0.00 | +92.2% | ✓ BEAT |
Q3 2024 | Sep 26, 2024 | $-0.22 | $-0.02 | +92.4% | ✓ BEAT |
Q3 2023 | Sep 15, 2023 | — | $-5.83 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-28.14 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-41.88 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-195.27 | — | — |
Q2 2019 | Apr 24, 2019 | — | $-2059.28 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-2384.03 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-2460.82 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-2524.45 | — | — |
Q4 2016 | Dec 31, 2016 | — | $3179.24 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-3529.39 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-2486.36 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-2467.88 | — | — |
Q4 2014 | Dec 31, 2014 | — | $-2988.23 | — | — |
Q2 2014 | Jun 30, 2014 | — | $-1549.45 | — | — |
Q4 2013 | Dec 31, 2013 | — | $-1045.00 | — | — |
Q2 2013 | Jun 30, 2013 | — | $-1032.60 | — | — |
Q4 2012 | Dec 31, 2012 | — | $-1008.32 | — | — |
Latest News
Biodexa Pharmaceuticals shares are trading lower after the company announced the pricing of its $10 million of 157,000 ADS units at $3.28.
📉 NegativeBenzinga•Dec 18, 2025, 05:42 PM
Biodexa Pharmaceuticals prices $10M best-efforts public offering; shares down
📉 NegativeSeeking Alpha•Dec 18, 2025, 01:43 PM
Biodexa Pharmaceuticals Prices $10M Public Offering, Selling 157,000 ADS Units At $3.28 And 2.89M Pre-Funded Units
➖ NeutralBenzinga•Dec 18, 2025, 01:40 PM
Biodexa Pharmaceuticals Shares Resume Trade
➖ NeutralBenzinga•Dec 16, 2025, 02:37 PM
Biodexa Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 42.26%
📈 PositiveBenzinga•Dec 16, 2025, 02:34 PM
Biodexa Enrolls First Three Patients Into Pivotal Phase 3 Serenta Trial In FAP
📈 PositiveBenzinga•Dec 1, 2025, 01:32 PM
Biodexa Pharmaceuticals Announces University of Bonn, Germany Screening Participants For Phase 3 Serenta Study Evaluating eRapa In Familial Adenomatous Polyposis
📈 PositiveBenzinga•Nov 24, 2025, 01:33 PM
BDRX stock has given up its prior gain. Biodexa shares were trading higher after the company announced that the European Medicines Agency approved its clinical trial application for the Phase 3 Serenta trial.
➖ NeutralBenzinga•Nov 3, 2025, 02:23 PM
Biodexa shares are trading higher after the company announced that the European Medicines Agency approved its clinical trial application for the Phase 3 Serenta trial.
📈 PositiveBenzinga•Nov 3, 2025, 01:38 PM
Biodexa Announces Approval Of Clinical Trial Application By European Medicines Agency For Phase 3 Serenta Trial
📈 PositiveBenzinga•Nov 3, 2025, 01:34 PM
Biodexa Pharmaceuticals Files For Mixed Shelf Of Up To $100M
➖ NeutralBenzinga•Sep 26, 2025, 09:04 PM
Biodexa Launches Registrational Phase 3 Trial Of eRapa For Familial Adenomatous Polyposis
📈 PositiveBenzinga•Sep 8, 2025, 11:02 AM
Biodexa Enrolls First Patients Into Phase 3 Serenta Trial For Adenomatous Polyposis
📈 PositiveBenzinga•Aug 18, 2025, 12:32 PM
Frequently Asked Questions about BDRX
What is BDRX's current stock price?
Biodexa Pharmaceuticals Plc (BDRX) is currently trading at $3.64 per share. The stock has moved -12.29% today.
What is the analyst price target for BDRX?
No analyst price targets are currently available for this stock.
What sector is Biodexa Pharmaceuticals Plc in?
Biodexa Pharmaceuticals Plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BDRX's market cap?
Biodexa Pharmaceuticals Plc has a market capitalization of $0.00 billion, making it a small-cap company.
Does BDRX pay dividends?
No, Biodexa Pharmaceuticals Plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIVI
BioVie Inc.
$1.41
Mkt Cap: $0.0B
CANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
ESLA
Estrella Immunopharma, Inc.
$1.69
Mkt Cap: $0.1B
GLMD
Galmed Pharmaceuticals Ltd.
$0.85
Mkt Cap: $0.0B
GNPX
Genprex, Inc.
$2.13
Mkt Cap: $0.0B
GRI
GRI Bio, Inc.
$0.34
Mkt Cap: $0.0B
INM
InMed Pharmaceuticals Inc.
$1.19
Mkt Cap: $0.0B
JAGX
Jaguar Health, Inc.
$1.17
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
Explore stocks similar to BDRX for comparison